Netzel M, Hopp R J, Buzzas R, Dowling P, Palmeiro E, Bewtra A K
Allergic Disease Center, Creighton University School of Medicine, Omaha, Neb.
Chest. 1993 Feb;103(2):484-7. doi: 10.1378/chest.103.2.484.
Inhaled amiloride has been recently demonstrated to have an effect on the decline of pulmonary function in patients with cystic fibrosis. Other diuretics have been demonstrated to provide protection against bronchoconstriction in asthmatic subjects. We report on the effect of inhaled amiloride on cold air hyperventilation challenge (CAHC) and methacholine challenge in asthmatics. We studied nine subjects with mild-moderate asthma in a double-blind, placebo-controlled, crossover study. Our results showed amiloride did not significantly protect against the bronchoconstriction induced by CAHC. Inhaled amiloride did not affect FEV1 in the hour after inhalation, and there was no significant difference between placebo or amiloride on the dose of methacholine causing a 20 percent fall in FEV1. Inhaled amiloride appears not to have a profile of action as previously seen with inhaled furosemide.
最近有研究表明，吸入阿米洛利对囊性纤维化患者肺功能的下降有影响。其他利尿剂已被证明可预防哮喘患者的支气管收缩。我们报告了吸入阿米洛利对哮喘患者冷空气过度通气激发试验（CAHC）和乙酰甲胆碱激发试验的影响。我们在一项双盲、安慰剂对照、交叉研究中对9名轻中度哮喘患者进行了研究。我们的结果显示，阿米洛利并不能显著预防CAHC诱发的支气管收缩。吸入阿米洛利在吸入后1小时内对第一秒用力呼气容积（FEV1）没有影响，在导致FEV1下降20%的乙酰甲胆碱剂量方面，安慰剂和阿米洛利之间没有显著差异。吸入阿米洛利似乎没有吸入呋塞米以前所显示的作用模式。
